LGVN: Positive Trial Update and First Contract
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. The...
278 Views
LGVN: Focus and Cost Controls Improve Outlook
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under...
193 Views
LGVN: Focus and Cost Controls Improve Outlook
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under...
305 Views
SPAC Talk: Which IBC Deals Could Be Under Threat?
KEY HIGHLIGHTS The haves.... The momentum of new deals continues to flow strongly. Ten new IBC deals have been announced so far in October, with a...
706 Views
Longeveron Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 9/21
Longeveron Inc. (“Longeveron”) is a leading clinical stage biotechnology company developing cell therapies for chronic aging-related diseases and...
46 Views